Synthesis and Assembly of Self-Complementary Cavitands
作者:Adam R. Renslo、Fabio C. Tucci、Dmitry M. Rudkevich、Julius Rebek
DOI:10.1021/ja993922e
日期:2000.5.1
Cavitands with self-complementary shapes (3 and 4) were prepared by the covalent attachment of adamantane guest molecules to the upper rim of the host structures. Relatives of the “self-folding” cavitands 2, these new structures possess a seam of intramolecular hydrogen bonds that stabilize the folded conformation. Their self-complementary shapes result in the formation of noncovalent dimers of considerable
具有自互补形状的空腔 (3 和 4) 是通过将金刚烷客体分子共价连接到主体结构的上缘来制备的。作为“自折叠”空腔 2 的亲属,这些新结构具有稳定折叠构象的分子内氢键接缝。它们的自互补形状导致形成具有相当大的动力学和热力学稳定性的非共价二聚体(-ΔG295 = 4.5 kcal/mol for 3a and 6.5 kcal/mol for 4a in p-xylene-d10)。空腔 3 和 4 的二聚反应是可逆的,并受溶剂和温度的控制。二聚化过程在焓上是有利的,熵是相反的,并且伴随着显着的焓-熵补偿发生。
Rationalization of Benzazole-2-carboxylate versus Benzazine-3-one/Benzazine-2,3-dione Selectivity Switch during Cyclocondensation of 2-Aminothiophenols/Phenols/Anilines with 1,2-Biselectrophiles in Aqueous Medium
作者:Tejas M. Dhameliya、Sumit S. Chourasiya、Eshan Mishra、Pradeep S. Jadhavar、Prasad V. Bharatam、Asit K. Chakraborti
DOI:10.1021/acs.joc.7b01548
日期:2017.10.6
insights of these cyclocondensation reactions using the hard–soft acid–base principle, quantum chemical calculations (density functional theory), and orbital interaction studies rationalize the selectivityswitch of benzothiazole-2-carboxylates versus benzazine-3-ones/benzazine-2,3-diones. The presence of water facilitates these cyclocondensation reactions by lowering of the energy barrier.
[EN] TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES<br/>[FR] DÉRIVÉS DE TÉTRAHYDROFURO[3,2-B]PYRROL-3-ONE COMME INHIBITEURS DE CYSTÉINE PROTÉASES
申请人:AMURA THERAPEUTICS LTD
公开号:WO2009144450A1
公开(公告)日:2009-12-03
A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein one of R1 and R2 is H, and the other is selected fromC1-8-alkyl, C3-6-cycloalkyl and C1-8-alkyl-C5-10-aryl; R3 is selected from tert-butyl, cyclopentyl and 1-methylcyclopentyl; R9 is selected from the following: (F). The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of various diseases.
Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
申请人:Ackermann Jean
公开号:US20070129544A1
公开(公告)日:2007-06-07
The invention is concerned with novel substituted piperidine derivatives of formula (I)
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.